Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cornelia Liedtke1, Chafika Mazouni1, Kenneth R Hess1

  • 1From the Departments of Breast Medical Oncology, Biostatistics and Applied Mathematics, and Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, University of Münster, Münster, Germany; Department of Obstetrics and Gynecology, Marseille Public Hospital System, Marseille; and Breast Cancer Unit and Translational Research Unit UPRES03535, Institut Gustave Roussy, Villejuif, France.

Summary

Triple-negative breast cancer (TNBC) patients show higher complete response rates to neoadjuvant chemotherapy. However, TNBC patients with residual disease face significantly worse survival outcomes, especially within the first three years post-treatment.